Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries announces FDA acceptance of sNDA Filing for pediatric indication for QNASL


Tuesday, 13 May 2014 08:30am EDT 

Teva Pharmaceutical Industries Ltd:Says U.S. Food and Drug Administration (FDA) accepts for review the supplemental new drug application (sNDA) for a lower dose QNASL Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age.QNASL is a waterless nasal allergy aerosol available only by prescription.